Earnings calls

Health.Global concall ledger

Every earnings call for HCG — management tone, guidance, KPIs and promise tracking, quarter by quarter.

HCG · 5 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 26 May 2026Call held 26 May 2026

HCG Q4 FY26 Earnings Call Transcript & Analysis

FY26 Revenue₹2,545 cr+15% YoYFY26 Adjusted EBITDA₹471.1 cr+19% YoYFY26 Adjusted EBITDA Margin18.5%+1% YoY

FY26 Revenue ₹2,545 cr (+15% YoY); FY26 Adjusted EBITDA ₹471 cr (+19% YoY); FY26 Adjusted EBITDA Margin 18.5% (+1% YoY). FY26 Revenue: ₹2,545 crore, up 15% YoY.

Read full transcript & analysis

Q3 FY26Published 09 Feb 2026Call held 09 Feb 2026

HCG Q3 FY26 Earnings Call Transcript & Analysis

Revenue₹633 cr+13% YoYAdjusted EBITDA₹111 cr+20% YoYEBITDA Margin17.5%

Revenue ₹633 cr (+13% YoY); Adjusted EBITDA ₹111 cr (+20% YoY); EBITDA Margin 17.5%. Revenue grew 13.4% YoY to INR 633 crore in Q3 FY26.

Read full transcript & analysis

Q2 FY26Published 04 Dec 2025Call held 04 Dec 2025

HCG Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹2,200 crEBITDA₹396 cr

Revenue ₹2,200 cr; EBITDA ₹396 cr. Revenue of ₹2,200 crores in FY2025, growing at a 15% CAGR (FY20-25).

Read full transcript & analysis

Q4 FY25Published 26 May 2025Call held 26 May 2025

HCG Q4 FY25 Earnings Call Transcript & Analysis

Adjusted EBITDA FY25₹396.3 cr+17% YoYAdjusted EBITDA Margin FY2517.8%PAT FY25₹44 cr

Adjusted EBITDA FY25 ₹396 cr (+17% YoY); Adjusted EBITDA Margin FY25 17.8%; PAT FY25 ₹44 cr. Revenue (ex-Milann) grew 20% in Q4 FY25 to INR571.1 crores.

Read full transcript & analysis

Q3 FY25Published 06 Mar 2025Call held 06 Mar 2025

HCG Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹559 cr+19% YoYAdjusted EBITDA₹92.3 cr+15% YoYAdjusted EBITDA Margin16.5%

Revenue ₹559 cr (+19% YoY); Adjusted EBITDA ₹92 cr (+15% YoY); Adjusted EBITDA Margin 16.5%. Revenue of INR 559 crores, up 19% YoY.

Read full transcript & analysis